FRI is pleased to announce that Drs. Michael S. Gordon (MPI) and Thomas R. Blue (Co-I), along with Dr. Lauren Brinkley-Rubinstein (MPI, contact) Associate Professor in the Department of Population Health Sciences at Duke University and Dr. Curt Beckwith (MPI) from The Miriam Hospital/Rhode Island Hospital and Alpert Medical School at Brown University have received funding from the National Institute on Drug Abuse through the “Ending the HIV Epidemic: Focus on Justice Populations with SUD” R61/R33 Clinical Trial grant mechanism. The project titled, “NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings” proposes to conduct a hybrid implementation-effectiveness type 2 study to optimize and test the efficacy of a LAI PrEP + buprenorphine (XR-B) co-packaged intervention among people in carceral and community re-entry settings in Ending the Epidemic Sites in Maryland and Washington, DC. The investigative team successfully completed the R61 phase and will transition to the R33 phase. The study specific aims are: Aim 1 (R61): Develop the intervention protocol for delivery of LAI PrEP + XR-B; Aim 2 (R33): Evaluate implementation facilitation as a strategy to support co-located LAI PrEP + XR-B in carceral and re-entry settings; and Aim 3 (R33): Compare the effectiveness of LAI PrEP + XR-B to oral PrEP + SL-B. Our long-term goal is to 1) provide guidance on how to implement LAI interventions in these settings; and 2) generate evidence relevant to the efficacy of co packaging LAI PrEP + XR-B to improve adherence and continuation of PrEP and buprenorphine.